Biogen PE ratio BIIB

Share price divided by earnings per share over the last twelve months, since 2010.

Today, Oct 23, 2026: 44.4×
10-year median: 16.1×
Against its 10-year history: 100th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.9× to 44.4×
Peer median: 41.6×

Biogen's PE ratio is 44.4× as of Oct 23, 2026: a share price of $250.69 against $5.65 of earnings per share over the last twelve months.

That is above its ten-year median of 16.1×, higher than on 100% of days in the last ten years.

Over that time it ranged from 7.9× in Sep 2020 to 44.4× in Oct 2026.

The median for 10 large drugmakers of a similar size is 41.6×.

PE ratio over time

median 16.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	44.4×	15.0×	44.4×
2025	16.1×	10.3×	16.6×
2024	13.7×	13.2×	28.9×
2023	25.7×	12.3×	25.7×
2022	14.1×	14.0×	23.4×
2021	23.5×	8.4×	27.5×
2020	8.1×	7.9×	10.9×
2019	10.7×	8.2×	21.8×
2018	19.0×	18.1×	28.8×
2017	19.5×	15.6×	22.2×
2016	16.0×	14.1×	18.5×
2015	20.0×	18.1×	38.4×
2014	32.4×	28.7×	44.4×
2013	38.9×	25.0×	40.8×
2012	25.4×	23.1×	28.5×
2011	22.9×	16.1×	26.9×
2010	16.6×	13.6×	16.9×

Against its peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

Company	PE ratio
BIIBBiogen	44.4×
JAZZJazz Pharmaceuticals	14.6×
BMYBristol-Myers Squibb	13.5×
BMRNBiomarin Pharmaceutical	151×
CORTCorcept Therapeutics	204×
PTGXProtagonist Therapeutics	134×
TGTXTG Therapeutics	19.8×
PFEPfizer	39.5×
ALKSAlkermes plc.	115×
GILDGilead Sciences	n/m
AMRXAmneal Pharmaceuticals	41.6×
Peer median	41.6×

Where Biogen ranks

#31of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Biogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.